Pre-made Muromonab benchmark antibody ( Whole mAb, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants. It is a monoclonal antibody targeted at the CD3 receptor, a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans.
| Products Name (INN Index) | Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
|---|---|
| INN Name | Muromonab |
| Target | CD3E |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2a |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Discontinued |
| 100% SI Structure | 1sy6:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 1988 |
| Year Recommended | 1989 |
| Companies | Cancer Research UK,Ortho-McNeil,XOMA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Diabetes mellitus,Graft-versus-host disease,Renal transplant rejection,Rheumatoid arthritis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD3E |
| Package |
